Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

Go back to Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Pfizer Inc. (NYSE: PFE) Delayed: 30.15 +0.20 (0.67%)
Previous Close $29.95    52 Week High $37.39 
Open $30.51    52 Week Low $28.25 
Day High $30.65    P/E 18.27 
Day Low $30.14    EPS $1.65 
Volume 7,234,302